| Autor: |
Valarcher JF; Department of Clinical Sciences, Swedish University of Agricultural Sciences, 750 07 Uppsala, Sweden., Hägglund S; Department of Clinical Sciences, Swedish University of Agricultural Sciences, 750 07 Uppsala, Sweden., Näslund K; Department of Clinical Sciences, Swedish University of Agricultural Sciences, 750 07 Uppsala, Sweden., Jouneau L; Université Paris-Saclay, INRAE, UVSQ, VIM, 78350 Jouy-en-Josas, France., Malmström E; Department of Clinical Sciences, Swedish University of Agricultural Sciences, 750 07 Uppsala, Sweden., Boulesteix O; INRAE, PFIE, 37380 Nouzilly, France., Pinard A; INRAE, PFIE, 37380 Nouzilly, France., Leguéré D; INRAE, PFIE, 37380 Nouzilly, France., Deslis A; INRAE, PFIE, 37380 Nouzilly, France., Gauthier D; INRAE, PFIE, 37380 Nouzilly, France., Dubuquoy C; Université Paris-Saclay, INRAE, UVSQ, VIM, 78350 Jouy-en-Josas, France., Pietralunga V; Université Paris-Saclay, INRAE, UVSQ, VIM, 78350 Jouy-en-Josas, France., Rémot A; INRAE, Université de Tours, ISP, 37380 Nouzilly, France., Falk A; Department of Chemistry-BMC, Uppsala University, 752 37 Uppsala, Sweden., Shevchenko G; Department of Chemistry-BMC, Uppsala University, 752 37 Uppsala, Sweden., Bergström Lind S; Department of Chemistry-BMC, Uppsala University, 752 37 Uppsala, Sweden., Von Brömssen C; Department of Energy and Technology, Swedish University of Agricultural Sciences, 750 07 Uppsala, Sweden., Vargmar K; Department of Biomedicine and Veterinary Public Health, Swedish University of Agricultural Sciences, 750 07 Uppsala, Sweden., Zhang B; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA., Kwong PD; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA., Rodriguez MJ; Inmunología y Genética Aplicada, S.A. (INGENASA), 28037 Madrid, Spain., Garcia Duran M; Inmunología y Genética Aplicada, S.A. (INGENASA), 28037 Madrid, Spain., Schwartz-Cornil I; Université Paris-Saclay, INRAE, UVSQ, VIM, 78350 Jouy-en-Josas, France., Taylor G; The Pirbright Institute, Woking, Surrey GU24 0NF, UK., Riffault S; Université Paris-Saclay, INRAE, UVSQ, VIM, 78350 Jouy-en-Josas, France. |
| Abstrakt: |
The induction of long-lasting clinical and virological protection is needed for a successful vaccination program against the bovine respiratory syncytial virus (BRSV). In this study, calves with BRSV-specific maternally derived antibodies were vaccinated once, either with (i) a BRSV pre-fusion protein (PreF) and Montanide TM ISA61 VG (ISA61, n = 6), (ii) BRSV lacking the SH gene (ΔSHrBRSV, n = 6), (iii) a commercial vaccine (CV, n = 6), or were injected with ISA61 alone ( n = 6). All calves were challenged with BRSV 92 days later and were euthanized 13 days post-infection. Based on clinical, pathological, and proteomic data, all vaccines appeared safe. Compared to the controls, PreF induced the most significant clinical and virological protection post-challenge, followed by ΔSHrBRSV and CV, whereas the protection of PreF-vaccinated calves was correlated with BRSV-specific serum immunoglobulin (Ig)G antibody responses 84 days post-vaccination, and the IgG antibody titers of ΔSHrBRSV- and CV-vaccinated calves did not differ from the controls on this day. Nevertheless, strong anamnestic BRSV- and PreF-specific IgG responses occurred in calves vaccinated with either of the vaccines, following a BRSV challenge. In conclusion, PreF and ΔSHrBRSV are two efficient one-shot candidate vaccines. By inducing a protection for at least three months, they could potentially improve the control of BRSV in calves. |
